ACT 4: Review of renal therapies prior to SGLT-2 inhibitor therapy

1. Intensive HbA1c control offers a consistent benefit over standard HbA1c control, with meta-analysis of cumulative studies showing a RRR of __% for macroalbuminuria.

2. From the ADVANCE-ON trial, intensive HbA1c control reduced the risk of ESRD by __% compared to standard HbA1c control.

3. There is an inverse relationship between reducing blood pressure and overall renal protection; the lower the blood pressure, the greater the overall renal protection observed:

4. The results of which trial indicate that multifactorial risk factor interventions lower cardiovascular complications, risk of nephropathy and all-cause mortality?

5. An intensive multifactorial intervention strategy reduces the risk of which of the following microvascular complications of T2DM?

6. The BENEDICT trial evaluating primary prevention of new renal events in T2DM compared which agent(s) to placebo?

7. Data from the BENEDICT trial and the ROADMAP study show that the use of which drug classes are significantly associated with a reduction in the development of new microalbuminuria?

8. In T2DM with established nephropathy, the IDNT demonstrated the superiority of which agent in respect of renal mortality outcomes?

9. The primary outcome of the RENAAL study included:

10. Because of the potential for development of hyperkalaemia and hypotension when using RAAS inhibitors, the use of these agents are limited in patients with: